Diagnosis

    LupusRheumatoid ArthritisPsoriatic ArthritisScleradermaOsteoarthritis (Knee)

    Are you currently on Medication for this Disease?

    YesNo

    **Currently Open For Enrollment**

    Eli Lilly – Protocol I4V-MC-JAHZ: A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 3 Study of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)

    Learn More

    **Now Open For Enrollment**

    Aurora –  A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (Voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Nephritis

    Learn More

    ** Now Open For Enrollment **
    Janssen Research & Development, LLC / “A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Ustekinumab in Subjects with Active Systemic Lupus Erythematosus”

    Clinical Trials

    **Now Open ForEnrollment**
    GlaxoSmithKline / “A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 104- Week Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination with Rituximab to Adult Subjects with Systemic Lupus Erythematosus (SLE)”

    Clinical Trials

    **Now Open For Enrollment**
    Part A
    A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

    Clinical Trials

    Part B
    A 2-Part Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of BIIB059 in Subjects with Systemic Lupus Erythematosus and Active Skin Manifestations and in Subjects with Active Cutaneous Lupus Erythematosus with or without Systemic Manifestations

    Clinical Trials

    **Now Open ForEnrollment**
    A randomized, double-blind, placebo-controlled multicenter study of secukinumab to evaluate the safety, tolerabilityand efficacy up to 2 years in patients with active non-radiographic axial spondyloarthritis

    Clinical Trials

    **Now Open For Enrollment**
    A RANDOMIZED DOUBLE-BLIND PHASE 1b/2 COMBINED STAGGERED MULTIPLE DOSE ESCALATION STUDY OF BOS161721 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) PATIENTS ON A BACKGROUND OF LIMITED STANDARD OF CARE

    Clinical Trials

    New Patient Information

      Diagnosis

      LupusRheumatoid ArthritisPsoriatic ArthritisScleradermaOsteoarthritis (Knee)

      Are you currently on Medication for this Disease?

      YesNo